BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $211,398 | -10.6% | 4,640 | 0.0% | 0.02% | 0.0% |
Q4 2022 | $236,501 | -5.4% | 4,640 | 0.0% | 0.02% | -13.0% |
Q3 2022 | $250,000 | -16.1% | 4,640 | 0.0% | 0.02% | -8.0% |
Q2 2022 | $298,000 | -17.2% | 4,640 | 0.0% | 0.02% | -7.4% |
Q1 2022 | $360,000 | -15.1% | 4,640 | -6.1% | 0.03% | -12.9% |
Q4 2021 | $424,000 | +10.4% | 4,940 | +3.6% | 0.03% | +3.3% |
Q3 2021 | $384,000 | +19.3% | 4,770 | +19.2% | 0.03% | +15.4% |
Q2 2021 | $322,000 | -4.5% | 4,000 | 0.0% | 0.03% | -18.8% |
Q1 2021 | $337,000 | +5.0% | 4,000 | 0.0% | 0.03% | -3.0% |
Q4 2020 | $321,000 | -5.0% | 4,000 | -4.8% | 0.03% | -8.3% |
Q3 2020 | $338,000 | -6.6% | 4,200 | 0.0% | 0.04% | -12.2% |
Q2 2020 | $362,000 | +6.2% | 4,200 | 0.0% | 0.04% | -16.3% |
Q1 2020 | $341,000 | -2.8% | 4,200 | 0.0% | 0.05% | +28.9% |
Q4 2019 | $351,000 | +11.4% | 4,200 | +16.7% | 0.04% | +5.6% |
Q3 2019 | $315,000 | +6.8% | 3,600 | 0.0% | 0.04% | 0.0% |
Q2 2019 | $295,000 | +0.7% | 3,600 | 0.0% | 0.04% | -5.3% |
Q1 2019 | $293,000 | +23.6% | 3,600 | 0.0% | 0.04% | +15.2% |
Q4 2018 | $237,000 | -14.7% | 3,600 | 0.0% | 0.03% | -8.3% |
Q3 2018 | $278,000 | +4.5% | 3,600 | 0.0% | 0.04% | -5.3% |
Q2 2018 | $266,000 | +13.7% | 3,600 | 0.0% | 0.04% | +5.6% |
Q1 2018 | $234,000 | +0.4% | 3,600 | 0.0% | 0.04% | +2.9% |
Q4 2017 | $233,000 | +3.1% | 3,600 | 0.0% | 0.04% | +6.1% |
Q3 2017 | $226,000 | +3.7% | 3,600 | 0.0% | 0.03% | +3.1% |
Q2 2017 | $218,000 | +16.6% | 3,600 | 0.0% | 0.03% | +3.2% |
Q1 2017 | $187,000 | +16.9% | 3,600 | 0.0% | 0.03% | +14.8% |
Q4 2016 | $160,000 | -6.4% | 3,600 | 0.0% | 0.03% | -12.9% |
Q3 2016 | $171,000 | -19.7% | 3,600 | -23.4% | 0.03% | -26.2% |
Q2 2016 | $213,000 | -5.8% | 4,700 | -14.5% | 0.04% | -14.3% |
Q1 2016 | $226,000 | +7.6% | 5,500 | 0.0% | 0.05% | +36.1% |
Q4 2015 | $210,000 | +64.1% | 5,500 | +41.0% | 0.04% | +50.0% |
Q3 2015 | $128,000 | -36.9% | 3,900 | +34.5% | 0.02% | -25.0% |
Q2 2015 | $203,000 | +2.0% | 2,900 | 0.0% | 0.03% | -3.0% |
Q1 2015 | $199,000 | -17.8% | 2,900 | -12.1% | 0.03% | -23.3% |
Q4 2014 | $242,000 | +2.1% | 3,300 | 0.0% | 0.04% | 0.0% |
Q3 2014 | $237,000 | -85.1% | 3,300 | -85.0% | 0.04% | -85.7% |
Q2 2014 | $1,591,000 | -39.9% | 22,000 | -38.9% | 0.30% | -45.1% |
Q1 2014 | $2,649,000 | +19.1% | 36,000 | +12.5% | 0.55% | +22.3% |
Q4 2013 | $2,225,000 | -23.0% | 32,000 | -27.3% | 0.45% | -22.8% |
Q3 2013 | $2,890,000 | -22.7% | 44,000 | -18.5% | 0.58% | -34.5% |
Q2 2013 | $3,740,000 | – | 54,000 | – | 0.89% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |